5-Fluoroindole-2-Carboxylic Acid

5-Fluoroindole-2-Carboxylic Acid

SCHEMBL209759

O=C(O)c1cc2cc(F)ccc2[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 1.00
HPGD P15428 2/20 1.00
HSD17B10 Q99714 2/20 1.00
PDPK1 O15530 1/20 1.00
ALDH1A1 P00352 1/20 1.00
LMNA P02545 1/20 1.00
TSHR P16473 1/20 1.00
NFKB1 P19838 1/20 1.00
APEX1 P27695 1/20 1.00
CYP2C19 P33261 1/20 1.00
TDP1 Q9NUW8 1/20 1.00
FLT3 P36888 6/20 0.66
SMAD3 P84022 1/20 0.66
F7 P08709 1/20 0.64
F3 P13726 1/20 0.64
PIN1 Q13526 1/20 0.64
DAO P14920 2/20 0.59
MAPT P10636 1/20 0.59
SRD5A2 P31213 1/20 0.59
MLLT1 Q03111 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
5-Fluoroindole-2-Carboxylic Acid SCHEMBL213473 0.98 KDM4E (0.96) KDM4EHPGDHSD17B10PDPK1ALDH1A1
SCHEMBL20494483 0.86 KDM4E (0.76) KDM4EHPGDHSD17B10PDPK1ALDH1A1
SCHEMBL6323639 0.85 KDM4E (0.73) KDM4EHPGDHSD17B10PDPK1ALDH1A1
SCHEMBL29500509 0.85 KDM4E (0.74) KDM4EHPGDHSD17B10PDPK1ALDH1A1
SCHEMBL1144377 0.85 KDM4E (0.74) KDM4EHPGDHSD17B10PDPK1ALDH1A1
SCHEMBL31287868 0.84 KDM4E (0.71) KDM4EHPGDHSD17B10PDPK1ALDH1A1
SCHEMBL2730226 0.84 KDM4E (0.72) KDM4EHPGDHSD17B10PDPK1ALDH1A1
SCHEMBL250527 0.84 KDM4E (0.72) KDM4EHPGDHSD17B10PDPK1ALDH1A1
SCHEMBL213471 0.84 KDM4E (0.72) KDM4EHPGDHSD17B10PDPK1ALDH1A1
SCHEMBL31287858 0.82 KMT2A (0.78) KDM4EHPGDHSD17B10PDPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 895 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570632-B2 Indole derivatives and uses thereof for treating a cancer UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2026-03-10 US claimed
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
EP-4475953-A1 NMDAR ANTAGONISTS PREVENT AGEING AND AGING-ASSOCIATED CONDITIONS AND DISEASES THROUGH INCREASING 20S PROTEASOME ACTIVITY SAHIN, Fikret (TR) 2024-12-18 EP claimed
CN-119095622-A NMDAR antagonists prevent aging and aging-related conditions and diseases by increasing 20S proteasome activity 菲克雷特·萨欣 2024-12-06 CN claimed
US-20240398785-A1 SMALL MOLECULE DRUGS FOR THE INDUCTION OF TRAINED IMMUNITY THE UNIVERSITY OF CHICAGO (US) 2024-12-05 US claimed
EP-4175718-B1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIV CLAUDE BERNARD LYON (FR) 2024-10-02 EP claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO claimed
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2023-09-07 US claimed
WO-2023154014-A1 NMDAR ANTAGONISTS PREVENT AGEING AND AGING-ASSOCIATED CONDITIONS AND DISEASES THROUGH INCREASING 20S PROTEASOME ACTIVITY SAHIN FIKRET (TR) 2023-08-17 WO claimed
EP-4175718-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD - LYON 1 (FR) 2023-05-10 EP claimed
EP-0952154-A2 N-acyl and N-aroyl aralkyl amides Pfizer Products Inc. (US) 1999-10-27 EP claimed
WO-1999005319-A9 METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY RAPIGENE INC (US) 1999-06-17 WO claimed
CN-1212021-A Method and compositions for determining sequence of nucleic acid molecules RAPIGENE INC (US) 1999-03-24 CN claimed
WO-1999005319-A2 METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY RAPIGENE, INC. (US) 1999-02-04 WO claimed
EP-0868535-A2 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES Rapigene, Inc. (US) 1998-10-07 EP claimed
EP-0850320-A2 METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL DARWIN MOLECULAR CORPORATION (US) 1998-07-01 EP claimed
WO-1997027331-A9 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES 1997-10-09 WO claimed
WO-1997027331-A2 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES RAPIGENE, INC. (US) 1997-07-31 WO claimed
WO-1997027327-A2 METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL RAPIGENE, INC. (US) 1997-07-31 WO claimed
EP-0433112-A1 Modified gangliosides and the functional derivatives thereof FIDIA S.p.A. (IT) 1991-06-19 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570632-B2 Indole derivatives and uses thereof for treating a cancer CKS2, CSNK2A3, CSNK1A1L KDM4E 2594/4885HPGD 2278/4885HSD17B10 1111/4885
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER CSNK2A1, IDO1, CSNK2A3 KDM4E 1643/4885HPGD 872/4885HSD17B10 1818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.